SAN FRANCISCO – Novartis has formed an in-house molecular diagnostics unit in order to improve the co-development of companion diagnostics and drugs, a company official told GenomeWeb Daily News today.

The group, co-located in Cambridge, Mass., and Basel, Switzerland, was created in January and should have around 50 to 60 staffers by the end of the year, said Michael Nohaile, head of Novartis Molecular Diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.